Prosonix is an innovative speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by design
May 15, 2015
Prosonix enters Definitive Agreement to be acquired by Circassia Pharmaceuticals plc for up to £100 million in Cash
Sep 11, 2014
Prosonix Confirms the Potential of its Multi-Component Particle™ Technology for Developing Novel Inhaled Dual...
Sep 2, 2014
Prosonix’ Marketing Authorisation Application for PSX1001 – a Generic Version of GlaxoSmithKline’s Flixotide®...